Hologic Stock News

While COVID-19 has driven recent quarterly beats, the Street seems to be overlooking the better long-term positioning of Hologic's diagnostics business post-COVID-19. The pandemic greatly accelerated

Las Vegas, USA, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Molecular Diagnostics Market is Expected to Grow at a Substantial CAGR of 9.21% and is Contemplated to Reach USD 16.12 Billion by 2026, Estimates DelveInsight Molecular Diagnostics Market is contemplated to witness huge demand in the upcoming years due to rising infectious diseases and their diagnosis, the presence of global as well as regional manufacturers active in developing the Molecular Diagnostic products such as Qiagen, Roche, Molbio Diagnostics Pvt. Ltd., among others. Also, improving healthcare infrastructure, government initiatives in raising awareness regarding molecular diagnosis will contribute to the Molecular Diagnostics market growth in these regions. DelveInsight''s Molecular Diagnostics Market Insights and Forecast report provides the current and forecast Molecular Diagnostics Market, upcoming innovation in the devices, individual market shares, challenges, drivers and barriers, market trends, and key competitors in the Molecular Diagnostics Market.

Super Bowl LVI aired Sunday on NBC, a unit of Comcast Corp (NASDAQ: CMCSA). The Los Angeles Rams were the winners of the game and ended the NFL season as champions. Other winners for Super Bowl LVI co

Investors are optimistic about Hologic's (HOLX) impressive Breast Imaging and Interventional Breast Solutions business performance.

Investors are optimistic about Hologic's (HOLX) impressive Breast Imaging and Interventional Breast Solutions business performance.

Mary J. Blige stars in the medical technology company''s commercial.

The ongoing Covid-19 health crisis has caused many catastrophes both short- and long-term. One major issue that threatens to have sweeping consequences going forward is that many people have missed annual health screenings while in quarantine. Breast and cervical cancer screenings specifically have suffered a sharp decline, according to the CDC. To that end, medical

The stock price of Hologic (NASDAQ: HOLX) increased by 1.66% in the most recent trading session. This is why it happened.

Impressive performance by Hologic's (HOLX) Breast Imaging and Interventional Breast Solutions drove Q1 revenues.

Hologic Inc  HOLX reported Q1 FY22 sales of $1.47 billion, beating the consensus of $1.18 billion and the company's expectations of $1.1 billion - $1.15 billion. Thousands of new traders are learnin

HOLX earnings call for the period ending December 31, 2021.

Hologic (HOLX) delivered earnings and revenue surprises of 80.83% and 31.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?